Abstract
Mpox is an infectious disease transmitted through close contact. It is caused by the monkeypox virus, which is endemic to some countries of West and Central Africa. A multi-country outbreak of mpox occurred in 2022, and the UK experienced rapid community transmission associated with sexual contact, mainly, but not exclusively among networks of gay, bisexual, and other men who have sex with men (GBMSM). In response to the outbreak in the UK, a reactive mpox vaccination programme was targeted to those most at risk. We explore the uptake and course completion of mpox vaccination in GBMSM taking part in an online survey in 2023. Findings from this community sample indicate vaccination uptake in around two-thirds of participants meeting mpox proxy eligibility criteria with high levels of course completion among all and eligible participants that were ever vaccinated. Vaccine non-offer was a barrier to uptake, as nearly a third of those eligible but unvaccinated reported never having received an mpox vaccine offer. Continued targeting of vaccination to GBMSM at highest risk of mpox at SHS, with community-support, will help facilitate equitable uptake of vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics statement: Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UKHSA REGG.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
(jessica.edney{at}ukhsa.gov.uk)
(dawn.phillips{at}ukhsa.gov.uk)
(ruth.wilkie{at}wales.nhs.uk)
(david.reid{at}ucl.ac.uk)
(kathy.lowndes{at}ukhsa.gov.uk)
(erna.buitendam{at}ukhsa.gov.uk)
(katy.sinka{at}ukhsa.gov.uk)
(sema.mandal{at}ukhsa.gov.uk)
(c.mercer{at}ucl.ac.uk)
(john.saunders{at}uksa.gov.uk)
(hamish.mohammed{at}ukhsa.gov.uk)
(dana.ogaz{at}ukhsa.gov.uk)
Ethics statement: Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UKHSA REGG.
Funding: This study did not receive any funding.
Competing interests: Authors have no competing interests to declare.
Data availability statement: The data that support the findings of this study are available upon reasonable request from the UK Health Security Agency (UKHSA). Requests can be directed to riish_survey{at}ukhsa.gov.uk.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.